We assume the reason for this is the abundant presence of PD-L1+ tumor cells that can block systemic CD8+ T cell immunity mounted by aFP treatment in the untreated contralateral tumor cells 12 days after aFP treatment since it is indicated by the survival benefit when using anti-PD-1 inhibitor in the aFP + anti-PD-1 group. The gene discussed is CD8A; the disease is neoplasm.